SJOGREN-LARSSON SYNDROME (ALDH3A2) GENE PANEL BY NGS, EDTA BLOOD

image not found

NABL Cap Accredited     
The Sjogren-Larsson Syndrome (ALDH3A2) Gene Panel by NGS is a comprehensive genetic test designed to detect mutations in the ALDH3A2 gene, which is associated with Sjogren-Larsson Syndrome—a rare inherited neurocutaneous disorder. The condition is characterized by ichthyosis, developmental delays, and spasticity due to impaired fatty aldehyde metabolism. This test is valuable for confirming diagnosis, identifying carriers, and supporting clinical management decisions. Metropolis Healthcare uses advanced Next-Generation Sequencing technology to provide accurate and early detection for affected individuals and families with suspected hereditary risk. 

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 19,950.00

Sample Type: EDTA BLOOD

Fasting Not Required


Notes: G0145

Frequently Asked Questions (FAQ's):

What does the ALDH3A2 Gene Panel test identify at Metropolis Healthcare?
It detects pathogenic mutations in the ALDH3A2 gene linked to Sjogren-Larsson Syndrome.

Who should consider this test at Metropolis Healthcare?
Individuals with symptoms such as congenital ichthyosis, developmental delay, or spasticity, and those with a family history of the disorder.

How does Metropolis Healthcare perform this test?
Using high-precision Next-Generation Sequencing (NGS) for detailed gene analysis.

Which specimen is needed for testing at Metropolis Healthcare?
EDTA whole blood sample.

How long do results take from Metropolis Healthcare?
Usually 2–4 weeks depending on the genetic complexity.

Is this test useful for carrier screening and genetic counselling?
Yes, Metropolis Healthcare supports reproductive planning and counselling for families at risk.

Does Metropolis Healthcare offer clinical interpretation guidance?
Yes, expert clinical interpretation and counselling are available to support result understanding.

Can this test differentiate from other neurocutaneous disorders?

Yes, comprehensive gene analysis improves diagnostic accuracy and avoids misdiagnosis 

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab